Last reviewed · How we verify
fhB7H3.CAR-Ts
At a glance
| Generic name | fhB7H3.CAR-Ts |
|---|---|
| Also known as | B7H3 targeting chimeric antigen receptor T cells |
| Sponsor | The Affiliated Hospital of Xuzhou Medical University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer (PHASE1, PHASE2)
- Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fhB7H3.CAR-Ts CI brief — competitive landscape report
- fhB7H3.CAR-Ts updates RSS · CI watch RSS
- The Affiliated Hospital of Xuzhou Medical University portfolio CI